Theranostic trial of well differentiated neuroendocrine tumors (NETs) with somatostatin antagonists 68Ga-OPS202 and 177Lu-OPS201.

Volume: 35, Issue: 15_suppl, Pages: 4094 - 4094
Published: May 20, 2017
Abstract
4094 Background: Radiolabeled somatostatin receptor 2 (sstr2) antagonists have shown higher tumor uptake and tumor-to-organ ratios than agonists in preclinical models. We performed a phase I study to evaluate the safety and radiation dosimetry of the sstr2 antagonists 68 Ga-OPS202 and 177 Lu-OPS201 ( 68 Ga/ 177 Lu-DOTA-JR11) in patients (pts) with metastatic well differentiated NETs (NCT02609737). Efficacy data after 177 Lu-OPS201were recorded....
Paper Details
Title
Theranostic trial of well differentiated neuroendocrine tumors (NETs) with somatostatin antagonists 68Ga-OPS202 and 177Lu-OPS201.
Published Date
May 20, 2017
Volume
35
Issue
15_suppl
Pages
4094 - 4094
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.